A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 2, 2012, Pages 415-424

  De Jesus Acosta, Ana ^a   Oliver, George R ^b   Blackford, Amanda ^a   Kinsman, Katharine ^a   Flores, Edna I ^c   Wilfong, Lalan S ^c   Zheng, Lei ^a   Donehower, Ross C ^a   Cosgrove, David ^a   Laheru, Daniel ^a   Le, Dung T ^a   Chung, Ki ^d   Diaz, Luis A ^a,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Cancer Institute of Dallas   (United States)

^c PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chemotherapy; Pancreatic cancer; Survival; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; DOCETAXEL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANASARCA; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; FATIGUE; FEMALE; FUNCTIONAL STATUS; HAND FOOT SYNDROME; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84856741290     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1704-y     Document Type: Review

References (25)

1. HA Burris 3rd J Andersen, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D (Pubitemid 27251144)
2. D Cunningham I Chau DD Stocken, et al. 2009 Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 5513 5518 19858379 10.1200/JCO.2009.24.2446 1:CAS:528:DC%2BC3cXhtVWitrc%3D
3. L Dahan F Bonnetain M Ychou, et al. 2010 Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301) Gut 59 1527 1534 20947887 10.1136/gut.2010.216135 1:CAS:528:DC%2BC3cXhsFemurjO
4. V Heinemann D Quietzsch F Gieseler, et al. 2006 Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 3946 3952 16921047 10.1200/JCO.2005.05.1490 1:CAS:528:DC%2BD28Xps1Sit78%3D (Pubitemid 46630743)
5. R Herrmann G Bodoky T Ruhstaller, et al. 2007 Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the swiss group for clinical cancer research and the central European cooperative oncology group J Clin Oncol 25 2212 2217 17538165 10.1200/JCO.2006.09.0886 1:CAS:528:DC%2BD2sXnsVShtbw%3D (Pubitemid 46954645)
6. HL Kindler D Niedzwiecki D Hollis, et al. 2010 Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group B (CALGB 80303) J Clin Oncol 28 3617 3622 20606091 10.1200/JCO.2010.28.1386 1:CAS:528:DC%2BC3cXhtFSksb3I
7. MH Kulke MA Tempero D Niedzwiecki, et al. 2009 Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904 J Clin Oncol 27 5506 5512 19858396 10.1200/JCO.2009.22.1309 1:CAS:528:DC%2BC3cXhtVWitrY%3D
8. MJ Moore D Goldstein J Hamm, et al. 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group J Clin Oncol 25 1960 1966 17452677 10.1200/JCO.2006.07.9525 1:CAS:528:DC%2BD2sXmvVWmsr0%3D (Pubitemid 46972777)
9. PA Philip J Benedetti CL Corless, et al. 2010 Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205 J Clin Oncol 28 3605 3610 20606093 10.1200/JCO.2009.25.7550 1:CAS:528:DC%2BC3cXhtFSksb3O
10. E Poplin Y Feng J Berlin, et al. 2009 Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the eastern cooperative oncology group J Clin Oncol 27 3778 3785 19581537 10.1200/JCO.2008.20.9007 1:CAS:528:DC%2BD1MXhtFaitr3L
11. GP Stathopoulos K Syrigos G Aravantinos, et al. 2006 A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer Br J Cancer 95 587 592 16909140 10.1038/sj.bjc.6603301 1:CAS:528:DC%2BD28XovVWitLc%3D (Pubitemid 44325898)
12. E Van Cutsem WL Vervenne J Bennouna, et al. 2009 Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer J Clin Oncol 27 2231 2237 19307500 10.1200/JCO.2008.20.0238
13. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825
14. RL Fine DR Fogelman SM Schreibman, et al. 2008 The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis Cancer Chemother Pharmacol 61 167 175 17440727 10.1007/s00280-007-0473-0 1:CAS:528:DC%2BD2sXhtFSrtbbK (Pubitemid 47512638)
15. Fine RL, Moorer G, Sherman W et al (2009) Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol 27(suppl; abstr 4623)
16. EA Eisenhauer P Therasse J Bogaerts, et al. 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228 247 19097774 10.1016/j.ejca.2008.10.026 1:STN:280: DC%2BD1M%2Fgs12rug%3D%3D
17. A Jemal R Siegel J Xu, et al. 2010 Cancer statistics, 2010 CA Cancer J Clin 60 277 300 20610543 10.3322/caac.20073
18. S Jones X Zhang DW Parsons, et al. 2008 Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 1801 1806 18772397 10.1126/science.1164368 1:CAS:528:DC%2BD1cXhtFCrtLrL
19. S Yachida S Jones I Bozic, et al. 2010 Distant metastasis occurs late during the genetic evolution of pancreatic cancer Nature 467 1114 1117 20981102 10.1038/nature09515 1:CAS:528:DC%2BC3cXhtlCjtrvI
20. M Reni S Cereda E Bonetto, et al. 2007 Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma Cancer Chemother Pharmacol 59 361 367 16807732 10.1007/s00280-006-0277-7 1:CAS:528:DC%2BD28XhtlCksb%2FK (Pubitemid 46025523)
21. M Reni S Cordio C Milandri, et al. 2005 Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial Lancet Oncol 6 369 376 15925814 10.1016/S1470-2045(05)70175-3 1:CAS:528:DC%2BD2MXltFWktLw%3D (Pubitemid 40753742)
22. B Wacker T Nagrani J Weinberg, et al. 2007 Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies Clin Cancer Res 13 3913 3921 17606725 10.1158/1078-0432.CCR-06-2610 1:CAS:528:DC%2BD2sXntFymt78%3D (Pubitemid 47037599)
23. JL Van Laethem P Hammel F Mornex, et al. 2010 Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study J Clin Oncol 28 4450 4456 20837948 10.1200/JCO.2010.30.3446
24. JP Neoptolemos DD Stocken C Bassi, et al. 2010 Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 1073 1081 20823433 10.1001/jama.2010.1275 1:CAS:528:DC%2BC3cXhtFequ7nE
25. CA Iacobuzio-Donahue B Fu S Yachida, et al. 2009 DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer J Clin Oncol 27 1806 1813 19273710 10.1200/JCO.2008.17.7188 1:CAS:528:DC%2BD1MXltlSis7o%3D